logo-loader

Scancell Holdings CEO discusses new research programme into coronavirus vaccine

Published: 09:06 24 Apr 2020 EDT

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway speaks to Proactive London's Andrew Scott after revealing it's begun a research programme to develop a vaccine for the coronavirus.

The project, to be led by the company’s chief scientific officer Lindy Durrant, will aim to use the company’s clinical expertise in cancer to produce a cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against coronavirus.

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

11 hours, 49 minutes ago